Achieved Q4 2024 PEMGARDA™ (pemivibart) net product revenue of $13.8 million, representing 48% growth over Q3 2024 net product revenue…
Visionary sector leaders Dan Menichella and Jo Brewer, PhD join as Non-Executive DirectorsBringing strengths in strategy, immuno-oncology science execution from bench to…
The scholarship will recognize the core tenets of Monarch in awardees' nucleic acid purification research IPSWICH, Mass., March 17, 2025…
BANGALORE, India, March 17, 2025 /PRNewswire/ -- Micro Bioreactor System Market is Segmented by Type (48 Parallel, 24 Parallel), by…
-- Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by new…
WASHINGTON, March 13, 2025 /PRNewswire/ -- The World Vaccine Congress Washington 2025, the largest and most influential global vaccine event,…
NYC Building & Construction Industry Safety Fund program will equip local workers, contractors and staff with NARCAN® Nasal Spray and…
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc.…
Net sales for the year ended December 31, 2024 were $57.8 million, down 5.5% compared to $61.2 million for the…
GAITHERSBURG, Md. and BASEL, Switzerland, March 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS), a leading public health…